- Lwin, Thinzar M;
- Miyake, Kentaro;
- Murakami, Takashi;
- DeLong, Jonathan C;
- Amirfakhri, Siamak;
- Filemoni, Filemoni;
- Yoon, Sang Nam;
- Yazaki, Paul J;
- Shivley, John E;
- Datnow, Brian;
- Clary, Bryan M;
- Hoffman, Robert M;
- Bouvet, Michael
Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.